Medivir’s history

2016
MIV-818 was selected as a candidate drug (CD) from the company’s project for the treatment of hepatocellular carcinoma.
 
The subsidiary BioPhausia (Nordic Brands) was divested to Karo Pharma AB.
 
The exclusive rights to the hepatitis C project, MIV-802, was outlicensed to Trek Therapeutics.
2015
The first oncology project within hepatocellular cancer was generated from the new focus area oncology.
 
SEK 600 million was transferred to the shareholders through a voluntary redemption programme.
2014
MIV-802 was selected as a candidate drug for the treatment of hepatitis C infection.
 
Simeprevir approved in the EU and Russia for the treatment of adults with chronic hepatitis C.
 
Olysio and Adasuve launched in Sweden, Norway, Finland and Denmark.
2013
Simeprevir was was approved for the treatment of patients with chronic hepatitis C in Japan, Canada and USA.
 
MIV-247 was selected as a candidate drug and enters development for the treatment of neuropathic pain.
 
Registration application for Simeprevir submitted in Japan, USA and Europe.
2012
Positive phase III data reported for simeprevir, confirming that treatment with simeprevir in combination with interferon and ribavirin results in high cure rates, a good safety profile, and reduced treatment times.
2011
Global phase III trials of simeprevir begin.
 
The North American marketing rights to Xerclear are sold to Meda.
 
BioPhausia acquired in order to strengthen the commercial platform.
2010
Meda licenses the sales and marketing rights for Xerclear for North America, Mexico and Canada. Corresponding rights licensed by GlaxoSmithKline for OTC sales in Europe.
2009
Xerclear approved for sale in certain European markets and the US market.
2006
Phase III trials of Xerclear begin.
2004
Hepatitis C agreement signed with Tibotec/Janssen for simeprevir.
2000
Mimetrix UK acquired in order to strengthen and expand within the protease sphere.
1996
Medivir listed on the Stockholm Stock Exchange. Collaboration with Abbott begins.
1995
CCS, Clean Chemical Sweden AB, a Sweden-based manufacturer of skincare products, acquired.
1992
Collaboration agreements entered into with Eli Lilly for HIV, and with Wellcome.
1989
Collaboration agreement entered into with American Cyanamid for HIV.
1988
Medivir founded.

Page updated 13 December 2016